vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $27.5M, roughly 1.2× Sanara MedTech Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -5.9%, a 4.1% gap on every dollar of revenue. On growth, Sanara MedTech Inc. posted the faster year-over-year revenue change (4.6% vs -3.2%). Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $-2.4M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs -3.5%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
CLFD vs SMTI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $27.5M |
| Net Profit | $-614.0K | $-1.6M |
| Gross Margin | 33.2% | 93.2% |
| Operating Margin | -5.3% | 23.5% |
| Net Margin | -1.8% | -5.9% |
| Revenue YoY | -3.2% | 4.6% |
| Net Profit YoY | 67.8% | 5.3% |
| EPS (diluted) | $-0.04 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $27.5M | ||
| Q3 25 | $23.4M | $26.3M | ||
| Q2 25 | $49.9M | $25.8M | ||
| Q1 25 | $47.2M | $23.4M | ||
| Q4 24 | $29.7M | $26.3M | ||
| Q3 24 | $5.6M | $21.7M | ||
| Q2 24 | $48.8M | $20.2M | ||
| Q1 24 | $36.9M | $18.5M |
| Q4 25 | $-614.0K | $-1.6M | ||
| Q3 25 | $-9.1M | $-30.4M | ||
| Q2 25 | $1.6M | $-2.0M | ||
| Q1 25 | $1.3M | $-3.5M | ||
| Q4 24 | $-1.9M | $-1.7M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | $-447.0K | $-3.5M | ||
| Q1 24 | $-5.9M | $-1.8M |
| Q4 25 | 33.2% | 93.2% | ||
| Q3 25 | 53.2% | 92.9% | ||
| Q2 25 | 30.5% | 92.5% | ||
| Q1 25 | 30.1% | 92.2% | ||
| Q4 24 | 29.2% | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | 21.9% | 90.0% | ||
| Q1 24 | 7.7% | 89.8% |
| Q4 25 | -5.3% | 23.5% | ||
| Q3 25 | 10.3% | 11.2% | ||
| Q2 25 | 3.0% | -0.1% | ||
| Q1 25 | 0.6% | -8.9% | ||
| Q4 24 | -6.9% | 18.6% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | -4.7% | -14.3% | ||
| Q1 24 | -26.4% | -8.3% |
| Q4 25 | -1.8% | -5.9% | ||
| Q3 25 | -38.8% | -115.5% | ||
| Q2 25 | 3.2% | -7.8% | ||
| Q1 25 | 2.8% | -15.1% | ||
| Q4 24 | -6.4% | -6.5% | ||
| Q3 24 | — | -13.2% | ||
| Q2 24 | -0.9% | -17.4% | ||
| Q1 24 | -16.0% | -9.5% |
| Q4 25 | $-0.04 | $-0.32 | ||
| Q3 25 | $-0.65 | $-3.40 | ||
| Q2 25 | $0.11 | $-0.23 | ||
| Q1 25 | $0.09 | $-0.41 | ||
| Q4 24 | $-0.13 | $-0.18 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | $-0.04 | $-0.41 | ||
| Q1 24 | $-0.40 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $249.7M | $5.9M |
| Total Assets | $268.1M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $16.6M | ||
| Q3 25 | $106.0M | $14.9M | ||
| Q2 25 | $117.2M | $17.0M | ||
| Q1 25 | $112.0M | $20.7M | ||
| Q4 24 | $113.0M | $15.9M | ||
| Q3 24 | $129.0M | $16.3M | ||
| Q2 24 | $123.8M | $6.2M | ||
| Q1 24 | $142.9M | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | $2.2M | $30.1M | ||
| Q2 24 | $2.1M | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $249.7M | $5.9M | ||
| Q3 25 | $256.2M | $6.1M | ||
| Q2 25 | $264.5M | $35.4M | ||
| Q1 25 | $265.9M | $36.7M | ||
| Q4 24 | $267.4M | $39.4M | ||
| Q3 24 | $275.8M | $39.8M | ||
| Q2 24 | $274.6M | $41.7M | ||
| Q1 24 | $279.2M | $43.3M |
| Q4 25 | $268.1M | $72.9M | ||
| Q3 25 | $306.2M | $71.1M | ||
| Q2 25 | $314.7M | $98.8M | ||
| Q1 25 | $310.9M | $96.4M | ||
| Q4 24 | $303.2M | $88.1M | ||
| Q3 24 | $315.3M | $88.5M | ||
| Q2 24 | $318.1M | $73.4M | ||
| Q1 24 | $315.4M | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | 0.01× | 0.76× | ||
| Q2 24 | 0.01× | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $3.9M |
| Free Cash FlowOCF − Capex | $-2.4M | $3.9M |
| FCF MarginFCF / Revenue | -7.1% | 14.0% |
| Capex IntensityCapex / Revenue | 2.9% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $3.9M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | $7.9M | $2.7M | ||
| Q1 25 | $3.0M | $-2.0M | ||
| Q4 24 | $7.2M | $932.0K | ||
| Q3 24 | $22.2M | $2.1M | ||
| Q2 24 | $4.0M | $-1.4M | ||
| Q1 24 | $-5.7M | $-1.6M |
| Q4 25 | $-2.4M | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $7.5M | $902.7K | ||
| Q1 25 | $654.0K | $-3.7M | ||
| Q4 24 | $5.1M | $859.9K | ||
| Q3 24 | $18.2M | $2.0M | ||
| Q2 24 | $2.8M | $-1.5M | ||
| Q1 24 | $-7.7M | $-1.7M |
| Q4 25 | -7.1% | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | 15.1% | 3.5% | ||
| Q1 25 | 1.4% | -15.9% | ||
| Q4 24 | 17.1% | 3.3% | ||
| Q3 24 | 323.0% | 9.4% | ||
| Q2 24 | 5.8% | -7.3% | ||
| Q1 24 | -20.8% | -9.0% |
| Q4 25 | 2.9% | 0.3% | ||
| Q3 25 | 2.0% | 4.0% | ||
| Q2 25 | 0.8% | 6.8% | ||
| Q1 25 | 5.1% | 7.4% | ||
| Q4 24 | 7.0% | 0.3% | ||
| Q3 24 | 71.4% | 0.0% | ||
| Q2 24 | 2.5% | 0.3% | ||
| Q1 24 | 5.3% | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLFD
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
